Pharmaceutical Adulterant Testing: GMP Controls That Prevent Undeclared Drug Ingredients in Herbal Supplements

Last updated: 2026-04-10

When FDA laboratory analysis of Kian Pee Wan capsules — an herbal supplement marketed for appetite stimulation and weight gain — found both dexamethasone and cyproheptadine in the product, neither ingredient appeared anywhere on the label. The March 30, 2026 voluntary nationwide recall by Aphreseller (Buy-herbal.com) is a textbook illustration of a failure mode that has driven hundreds of dietary supplement enforcement actions over the past two decades: pharmaceutical drugs hidden inside products that consumers believe contain only herbal ingredients.

The product "worked." That is almost certainly why it contained undeclared drugs. Cyproheptadine produces measurable weight gain through serotonin antagonism. Dexamethasone drives appetite and metabolic shifts through corticosteroid activity. Both drugs create the effect consumers attribute to the herbal formula — chen pi, lian zi, fu ling, shan zha, mai ya, shi jun zi, huai shan — and neither one carries any warning on the label. Consumers had no way to know they were taking a potent corticosteroid alongside an antihistamine/appetite stimulant.

This article is not primarily about the Kian Pee Wan recall. It is about the testing and manufacturing controls that would have prevented it — and that your quality system needs in place right now if you manufacture, import, or distribute herbal dietary supplements. The regulatory framework exists. The testing methods exist. The gap, as usual, is in implementation.

Why Pharmaceutical Adulterants End Up in Herbal Supplements

Before addressing what testing catches pharmaceutical adulterants, it is worth understanding how they get in. Three distinct mechanisms drive most of the cases FDA investigates:

Deliberate Adulteration for Efficacy

The bluntest explanation: pharmaceutical adulterants make herbal products produce faster, more noticeable effects. A consumer who takes an appetite-stimulating herbal capsule and gains weight becomes a repeat customer. The economics of adulteration are straightforward — the drugs do what the herbs cannot do quickly enough to satisfy a customer expecting results. A 2019 study published in JAMA Internal Medicine found 776 dietary supplements in FDA warning databases between 2007 and 2016 that contained undeclared pharmaceutical ingredients, with 20% of those products containing more than one undeclared drug. The weight management and appetite category appears in that dataset alongside sexual enhancement and bodybuilding — all categories where "results" drive brand loyalty.

Supplier Fraud Upstream of the Manufacturer

Not every manufacturer who distributes an adulterated product intentionally added the drug. A raw material supplier — often located overseas — adulterates the botanical ingredient before it leaves their facility. The manufacturer receives the ingredient, reviews the supplier's Certificate of Analysis (COA) showing appropriate botanical content, and incorporates it into a finished product. The COA does not test for pharmaceutical co-contaminants. The manufacturer does not test for them either. The adulteration travels the entire supply chain undetected until FDA tests the finished product on store shelves — or in an online marketplace.

This is not a theoretical scenario. Studies of Chinese herbal medicine and Asian patent medicines have found that 24% or more of sampled products contain at least one synthetic pharmaceutical, and that approximately 32% of Asian patent medicines sold in California in one study contained undeclared pharmaceuticals or heavy metals. The supply chain problem is structural, not incidental.

Cross-Contamination at Shared Facilities

A contract manufacturer producing multiple product lines — some of which include pharmaceutical ingredients as intentional adulterants in separate product lines — can contaminate nominally clean products through inadequate equipment cleaning. This is less common than deliberate adulteration but is documented in FDA warning letters and consent decrees involving shared equipment without adequate cleaning validation.

The Regulatory Framework: What 21 CFR Part 111 Actually Requires

Understanding why adulteration is a GMP failure — not just a labeling problem — requires reading the specific provisions of 21 CFR Part 111, the dietary supplement cGMP regulation. Part 111 became effective for large manufacturers on June 25, 2007; for small manufacturers on August 24, 2009; and for very small manufacturers on June 25, 2010. There are no exemptions. Every dietary supplement manufacturer in the United States is subject to it.

Section 111.70(b) — Component Specifications

21 CFR § 111.70(b) requires you to establish specifications for the identity, purity, strength, and composition of each dietary ingredient component, including limits for contaminants that may adulterate or may lead to adulteration of the finished batch of dietary supplement. Read that last clause carefully: your specifications must address contaminants — not just the identity of the primary ingredient. For a botanical ingredient sourced from a supplier with documented adulteration patterns, a specification that addresses only botanical identity is not sufficient. It must also address the contamination risks specific to that ingredient category.

Section 111.70(e) — Finished Batch Specifications

21 CFR § 111.70(e) requires finished batch specifications that include limits for contaminants that may adulterate the finished product. A finished product specification for an appetite and weight gain supplement that does not list "no detectable pharmaceutical adulterants" — with a defined analytical method and acceptance criteria — is not compliant with what the regulation requires. This is where most small-to-midsize herbal supplement manufacturers have a visible gap.

Section 111.75(a)(1)(i) — The Critical Provision

21 CFR § 111.75(a)(1)(i) is the provision that most frequently drives enforcement action in adulteration cases. It requires that you conduct at least one appropriate test or examination to verify the identity of every dietary ingredient before use. The regulation is explicit: you cannot rely solely on a supplier's COA to confirm identity. You must have your own test or examination result. There is no exception to this requirement unless you petition FDA and receive an exemption — and no such petition has been granted for routine incoming testing obligations.

The practical implication: if you receive a botanical ingredient from an overseas supplier, their COA showing it is genuine chen pi does not satisfy your identity verification obligation. Your laboratory — or a contracted qualified laboratory — must perform an independent test on each incoming lot. A COA is corroborating documentation, not a substitute for your own testing.

Section 111.75(a)(2)(ii) — Supplier Qualification

21 CFR § 111.75(a)(2)(ii) allows reliance on a supplier's COA for non-dietary-ingredient components (excipients, packaging materials) only after you have qualified the supplier through a documented process that includes periodic re-qualification testing. Even this qualified-supplier COA reliance pathway does not extend to dietary ingredients, which must always be independently tested per § 111.75(a)(1)(i).

Section 111.75(c) — Finished Batch Testing

21 CFR § 111.75(c) requires that you verify that each finished batch meets all specifications established under § 111.70(e) before releasing product for distribution. If your finished batch specification includes "no detectable pharmaceutical adulterants," you must test for those adulterants before release. This is not discretionary. A finished batch that has not been tested against all of its specifications has not been properly released under Part 111.

Section 111.80 — Representative Sampling

21 CFR § 111.80 requires that samples be collected from representative portions of each lot for the tests and examinations required under § 111.75. Sampling must be documented, and sample sizes must be statistically adequate to represent the lot. A single capsule pulled for identity testing from a lot of 10,000 bottles does not satisfy this requirement.

Section 111.95 — Documentation

21 CFR § 111.95 requires documentation of all test and examination results, with records retained for a period equal to the shelf life plus one year, with a minimum of two years. If FDA inspects your facility and requests testing records for a component lot that was distributed six months ago, those records must exist and must be retrievable. "We tested it but didn't write it down" is not a defensible position.

The Adulteration Statutes: Beyond GMP

Failing the cGMP requirements of 21 CFR Part 111 is serious. But the Kian Pee Wan recall also implicates the adulteration provisions of the FD&C Act directly — provisions that carry independent enforcement weight regardless of GMP status.

21 U.S.C. § 342(a)(1) deems a food or supplement adulterated if it bears or contains any poisonous or deleterious substance which may render it injurious to health. Dexamethasone in a product consumed by a person on anticoagulants, NSAIDs, diabetes medications, or live vaccines — without any warning label — satisfies this standard. Cyproheptadine consumed by an elderly person, a patient with glaucoma or benign prostatic hyperplasia, or someone on MAOIs satisfies this standard.

21 U.S.C. § 342(a)(2)(C) deems a supplement adulterated if it contains an unapproved food additive — which includes any pharmaceutical drug ingredient not generally recognized as safe for use in dietary supplements.

21 U.S.C. § 342(f)(1)(A) deems a dietary supplement adulterated if a dietary ingredient in it presents a significant or unreasonable risk of illness under the conditions of use recommended in its labeling. A product marketed for weight gain in children or adults that contains an undeclared corticosteroid and an undeclared antihistamine easily meets this threshold.

A product containing undeclared prescription drug ingredients is also, simultaneously, an unapproved new drug under the FD&C Act. The moment dexamethasone is detected in a capsule labeled as an herbal formula, the product is no longer merely a mislabeled supplement — it is an illegally marketed drug. That distinction matters for the severity of enforcement exposure.

The Health Risks of Undeclared Dexamethasone and Cyproheptadine

Understanding the specific drugs found in the Kian Pee Wan recall helps illustrate why pharmaceutical adulterant screening cannot be limited to the most commonly searched-for drugs. FDA testing found two distinct pharmaceutical classes in one product — a corticosteroid and an antihistamine/appetite stimulant. Neither is benign, and neither would be expected by a consumer reading an herbal ingredient list.

Dexamethasone: Undeclared Corticosteroid

Dexamethasone is a potent synthetic corticosteroid approximately 25 times more potent than hydrocortisone. When consumed chronically without medical supervision:

Immunosuppression leaves consumers vulnerable to serious infections they cannot recognize because they lack any clinical context for their changed immune status.
HPA axis suppression occurs with regular dosing, meaning the adrenal glands reduce their own cortisol production. Abrupt cessation — which happens whenever a consumer runs out of "herbal" capsules — can precipitate adrenal insufficiency, a potentially life-threatening condition.
Drug interactions are numerous and serious: additive bleeding risk with anticoagulants and NSAIDs, hyperglycemia in diabetic patients, interaction with live vaccines contraindicated during corticosteroid therapy, and reduced efficacy of hypoglycemic agents.
Metabolic effects include fluid retention, hypokalemia, hypertension, and the classic Cushingoid features of prolonged steroid use — all presenting without any clinical explanation to the treating physician.
Ocular effects include elevation of intraocular pressure and accelerated cataract formation — relevant for any patient with glaucoma or diabetes.

Cyproheptadine: Undeclared Antihistamine and Appetite Stimulant

Cyproheptadine is a first-generation antihistamine with serotonin antagonist properties. It produces measurable weight gain via its effect on serotonin signaling — which is exactly why it appears in appetite stimulation products. What consumers do not know they are getting:

Sedation is a prominent and documented effect, particularly in first-generation antihistamines. Driving or operating machinery while unknowingly taking cyproheptadine represents an unwarned safety hazard.
Anticholinergic effects include urinary retention (contraindicated in benign prostatic hyperplasia), tachycardia, dry mouth, constipation, and in overdose, confusion and seizures.
Contraindications include elderly patients (falls risk, cognitive effects), patients with narrow-angle glaucoma, and patients on MAOIs, where the combination can produce hypertensive crisis.
Long-term consequences of chronic cyproheptadine exposure include significant weight gain beyond what the consumer intended, elevated blood pressure, and increased risk of developing insulin resistance.

The combination of these two drugs — one producing appetite and metabolic changes via corticosteroid activity, the other via serotonin antagonism — creates a pharmacologically active product that could plausibly harm a significant portion of the population that consumes herbal weight gain supplements. That population is not uniformly young and healthy.

Testing Controls That Would Have Prevented This Recall

The Kian Pee Wan recall was preventable at multiple points in the manufacturing and supply chain. Each of the following controls represents a specific GMP requirement that, if properly implemented, would have detected the adulterants before product reached consumers.

1. Incoming Component Identity Testing With Pharmaceutical Screening

The single most impactful control is also the one most commonly performed inadequately. 21 CFR § 111.75(a)(1)(i) requires identity testing of every dietary ingredient. But the test method matters as much as whether a test was performed at all.

Traditional botanical identity testing methods — thin-layer chromatography (TLC), organoleptic examination, microscopy — are appropriate for confirming botanical identity. They are not adequate for detecting pharmaceutical co-contaminants at the trace levels relevant to adulteration. A TLC test that confirms the presence of chen pi confirms that some of what you received is actually chen pi. It does not tell you whether dexamethasone is also present.

For herbal supplement manufacturers sourcing ingredients from overseas suppliers in markets with documented adulteration patterns, identity testing must include pharmaceutical adulterant screening using validated methods:

HPLC (High-Performance Liquid Chromatography) can screen for a defined panel of target compounds with good sensitivity and specificity.
LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) provides the highest sensitivity and can detect trace-level pharmaceutical adulterants across a broad compound panel in a single run. For high-risk ingredient categories, LC-MS/MS is the appropriate tier of incoming testing.
The panel must be risk-based. For an appetite stimulation product, the panel should explicitly include corticosteroids (dexamethasone, prednisone, betamethasone), antihistamines with appetite effects (cyproheptadine, promethazine), and other known appetite-related adulterants. Using a sexual enhancement panel on an appetite product — or vice versa — misses the actual risk.

2. Finished Product Pharmaceutical Adulterant Screening

Incoming component testing is the first line of defense. Finished product testing is the last. 21 CFR § 111.75(c) requires that finished batches meet all established specifications before release. If "no detectable pharmaceutical adulterants" is not in your finished product specification, it needs to be added today — and a validated LC-MS/MS method needs to be the test that confirms it.

A finished product pharmaceutical adulterant screen serves two functions: it catches contamination that entered via adulterated components (which incoming testing should have caught first), and it catches cross-contamination that occurred within your facility during manufacturing. These are distinct failure modes that require distinct controls. Both are your responsibility under Part 111.

3. Supplier Qualification With Methodology Audit

A supplier qualification program that results in an approved supplier list and COA reliance protocol is required under 21 CFR § 111.75(a)(2)(ii) for non-dietary-ingredient components. For dietary ingredients, the independent testing requirement under § 111.75(a)(1)(i) is not waived by qualification — but supplier qualification still matters because it informs your risk-based testing frequency and method selection.

For herbal ingredient suppliers in markets with documented adulteration patterns, qualification must go further than reviewing documentation. It must include:

Audit of the supplier's testing methodology — specifically whether they test for pharmaceutical co-contaminants and, if so, what method they use. A supplier who performs only botanical identity testing on outgoing product cannot vouch for pharmaceutical cleanliness.
Independent result confirmation — split-sample testing where your laboratory tests the same lot as the supplier and results are compared. Persistent discrepancies indicate either method inadequacy or intentional misrepresentation.
Periodic re-qualification — supplier qualification is not a one-time event. A supplier who passed re-qualification two years ago may have changed their own ingredient sourcing or testing practices. High-risk ingredient categories warrant annual or semi-annual re-qualification.

4. Risk-Based Product Category Specifications

Not all dietary supplement categories carry equal pharmaceutical adulteration risk. The documented adulteration patterns are concentrated in specific functional categories: sexual enhancement, weight loss and appetite stimulation, bodybuilding and muscle gain, and energy products. 21 CFR § 111.70 requires that specifications account for contamination risks — and for products in these high-risk categories, the contamination risk is pharmaceutical adulteration.

Your finished product specifications for an appetite stimulation product must explicitly list the pharmaceutical classes of concern — corticosteroids, antihistamines, stimulants, serotonin-active agents, anabolic hormones — with "not detected" acceptance criteria and a defined quantitation limit. This is not gold-plating. FDA inspectors reviewing a cGMP complaint for an appetite product will look for this specificity, and its absence is a direct observation point.

5. Full Lot Traceability

When adulterants are found — either by your testing or by FDA's — 21 CFR § 111.95 documentation requirements exist precisely to enable rapid lot isolation. Complete traceability means that for any finished product lot, you can identify every component lot used in its manufacture, the date of receipt, the supplier, the incoming test results, and the finished product test results. Without this, a recall becomes a guessing game about scope, and FDA will make unfavorable assumptions about the breadth of the problem.

The Traditional Chinese Medicine Context: Why Herbal Supplements Carry Elevated Risk

The Kian Pee Wan capsules present an important category-specific lesson that general supplement compliance guidance often overlooks. Traditional Chinese Medicine (TCM) products and Asian patent medicines occupy a well-documented high-risk position in the pharmaceutical adulteration landscape.

Research on this specific category is sobering:

A study of 2,600 Chinese herbal medicine samples found that approximately 24% contained at least one synthetic pharmaceutical.
Corticosteroids consistently rank among the top five adulterant classes found in TCM products, alongside antidiabetic agents, sedatives, sexual enhancement drugs, and analgesics.
The FDA's Health Fraud Product Database, which catalogues identified tainted products, contains hundreds of TCM and herbal products with confirmed pharmaceutical adulterants.
Since 2004, adulteration with banned pharmaceutical ingredients has driven approximately half of all FDA Class I drug recalls in the dietary supplement category.

This is not an accusation against any particular company or country of origin. It is a risk signal that must inform how you design your testing program for this ingredient category. If you manufacture products using TCM botanicals sourced from overseas suppliers, your incoming testing program must include pharmaceutical screening proportionate to the documented risk. A testing program designed for domestically sourced dietary ingredients may not be adequate for this supply chain.

What DSHEA Does and Does Not Protect

The Dietary Supplement Health and Education Act of 1994 (DSHEA) established the regulatory framework under which dietary supplements are sold in the United States without pre-market FDA approval. Some manufacturers misread this as meaning FDA oversight is minimal. That reading is incorrect.

DSHEA created a specific gap: FDA does not approve supplement formulations before market entry. The burden falls on FDA to demonstrate unsafety after a product is already on the market. This means a manufacturer can sell an herbal formula without submitting it to FDA for review — but it does not mean there are no standards. DSHEA requires that supplements be safe, properly labeled, and manufactured in accordance with applicable cGMP regulations (21 CFR Part 111). A product that contains undeclared dexamethasone and cyproheptadine is not a dietary supplement under DSHEA — it is an adulterated product and an unapproved new drug. DSHEA provides no cover for adulteration.

The post-market nature of FDA oversight does not reduce your manufacturing obligations. It increases the importance of your internal testing programs, because the first time FDA tests your product may be after it has been distributed nationwide. If FDA finds pharmaceutical adulterants, the recall scope is determined by distribution, not by lot boundaries — and the enforcement consequences begin immediately.

Compliance Action Plan for Herbal Supplement Manufacturers

If you manufacture or import herbal dietary supplements — particularly products in the appetite stimulation, weight management, or traditional botanical formula categories — here is the compliance roadmap I implement with clients at Certify Consulting:

Immediate — 30 Days

Audit your incoming component testing program against 21 CFR § 111.75(a)(1)(i). Confirm that every dietary ingredient lot receives an independent identity test from your facility or your contracted laboratory. If you are relying solely on supplier COAs, this is a cGMP deficiency that needs immediate correction.
Review your product specifications under § 111.70(b) and § 111.70(e) for all herbal and TCM-category products. Confirm that both component and finished batch specifications address pharmaceutical adulterant contamination with defined acceptance criteria.
Identify which products in your portfolio are in high-risk categories: appetite stimulation, weight management, sexual enhancement, energy, and traditional botanical formulas. These products require the highest level of pharmaceutical adulterant screening.

Medium-Term — 30 to 90 Days

Implement or expand LC-MS/MS pharmaceutical adulterant screening for incoming dietary ingredient lots and finished batches in high-risk product categories. If your laboratory does not have this capability, identify and qualify a contract laboratory with validated methods for pharmaceutical adulterant detection.
Build a risk-based pharmaceutical adulterant panel for each product category. The panel for an appetite supplement should include corticosteroids, antihistamines with serotonin activity, and known anabolic agents — not a generic sexual enhancement panel.
Conduct supplier audits or questionnaires targeting your highest-risk ingredient suppliers. Focus on their testing methodology for outgoing product, their supply chain visibility for raw material sourcing, and their history of adulteration-related complaints or regulatory action.

Ongoing Program Requirements

Trend your pharmaceutical adulterant testing data. One clean result from a supplier does not establish a pattern. Reviewing results across multiple lots from the same supplier over time reveals whether contamination is a random event or a systematic issue with that supply chain.
Maintain complete lot traceability records per § 111.95 for a minimum of two years from the date of manufacture, or the shelf life of the product plus one year, whichever is longer.
Review and update specifications annually as FDA's Health Fraud database and published research identify new adulterant targets in your product categories. The pharmaceutical adulteration problem is not static — new synthetic analogs and new drug categories appear in enforcement data regularly.

Rapid Reference: Compliance Checklist for Herbal Supplement Manufacturers

Control Area	Regulatory Requirement	Minimum Standard
Incoming identity testing	21 CFR § 111.75(a)(1)(i)	Independent test on each lot — not COA reliance
Component specifications	21 CFR § 111.70(b)	Must include pharmaceutical adulterant contaminant limits for high-risk categories
Finished batch specifications	21 CFR § 111.70(e)	Must include "no detectable pharmaceutical adulterants" with defined method
Finished batch testing	21 CFR § 111.75(c)	Validated LC-MS/MS screen before release for high-risk products
Supplier qualification	21 CFR § 111.75(a)(2)(ii)	Audit supplier testing methodology; periodic re-qualification
Representative sampling	21 CFR § 111.80	Statistically adequate sample size from each lot
Documentation and records	21 CFR § 111.95	All test results documented; retained per shelf life + 1 year minimum
Lot traceability	21 CFR § 111.95	Component lot linkable to finished product lot; enables complete recall scope determination

FAQ: Pharmaceutical Adulterants in Herbal Supplements

Q: My supplier provides a Certificate of Analysis with every shipment. Does that satisfy my testing obligation under 21 CFR § 111.75?
A: No. Section 111.75(a)(1)(i) requires that you conduct at least one appropriate test or examination to verify the identity of every dietary ingredient. There is no COA exception for dietary ingredients. The COA is corroborating documentation — it does not replace your obligation to independently verify identity and confirm the absence of adulterants relevant to your product category.

Q: We test our incoming botanicals by TLC for identity. Does that satisfy the pharmaceutical adulterant screening requirement?
A: TLC confirms botanical identity but is not adequate for detecting pharmaceutical co-contaminants at the trace levels associated with deliberate adulteration. For high-risk ingredient categories — any herbal ingredient used in appetite stimulation, weight management, sexual enhancement, or traditional Chinese medicine products — the identity testing program must include pharmaceutical adulterant screening using validated HPLC or LC-MS/MS methods. TLC alone is an incomplete program for these categories.

Q: How do we determine which pharmaceutical adulterants to screen for in our herbal products?
A: Your pharmaceutical adulterant panel should be built from a documented risk assessment for each product category, informed by: FDA's Health Fraud Product Database for confirmed adulterants in similar products, published peer-reviewed research on adulteration patterns in your ingredient categories, the functional claims of your product (which indicate the drug classes that would most plausibly drive the claimed effect), and any prior incidents in your supply chain. For an appetite stimulation product, corticosteroids and antihistamines with serotonin/appetite effects are the primary target classes based on documented enforcement history.

Q: What is the enforcement exposure if FDA finds pharmaceutical adulterants in our product?
A: A dietary supplement containing undeclared pharmaceutical drug ingredients is simultaneously an adulterated food under 21 U.S.C. § 342 and an unapproved new drug under the FD&C Act. FDA enforcement tools include voluntary recall (Class I classification is likely), mandatory recall under 21 U.S.C. § 350l, warning letter, injunctive relief, import alert, and criminal prosecution for knowing violations. The severity depends on whether FDA concludes the adulteration was deliberate, whether it was systematic across multiple products or lots, and whether there were prior compliance failures. A single lot recall with a strong CAPA response sits at one end of that spectrum; a pattern of adulterated products across multiple SKUs with a history of GMP deficiencies sits at the other.

Q: Can we continue distributing other products while one SKU is under recall for pharmaceutical adulteration?
A: Generally yes, if the recall is lot-specific and there is no indication that other products are similarly affected. However, FDA's recall investigation will include review of your manufacturing records, component supplier records, and laboratory testing program across related products. Any systematic GMP deficiency discovered during the investigation — for example, a testing program that relies entirely on supplier COAs for all herbal ingredients, not just the recalled product — can trigger a broader enforcement action. An internal assessment of all related products, with documented results, is strongly advisable before you conclude that the problem is contained.

The Bottom Line

The Kian Pee Wan recall demonstrates that pharmaceutical adulterants in herbal supplements are not an exotic compliance concern — they are a recurring, well-documented, and entirely preventable failure mode. The drugs found in this product were not difficult to detect. LC-MS/MS would have found both dexamethasone and cyproheptadine at the incoming component stage, at the finished batch stage, or both. The testing existed. The regulatory requirement to perform it existed. The gap was in implementation.

FDA's enforcement posture toward dietary supplements has consistently prioritized pharmaceutical adulteration as a high-risk violation category, and online distribution channels — including eBay, Amazon, and direct-to-consumer websites — have not reduced enforcement exposure. If anything, FDA's increased focus on marketplace accountability means that products sold through third-party online platforms face testing scrutiny they did not face when distribution was primarily through brick-and-mortar retail.

If your herbal supplement program does not currently include pharmaceutical adulterant screening as a documented, validated, and systematically implemented component of both incoming testing and finished batch release, it needs to. The regulatory requirement is not new. The testing methods are available. The enforcement consequences of waiting until FDA finds the problem are substantial.

For an assessment of your herbal supplement quality program against 21 CFR Part 111 requirements, contact Certify Consulting. We work with supplement manufacturers to close testing gaps before they become recall events.

Reference: FDA recall notice — Aphreseller (Buy-herbal.com) Issues Voluntary Nationwide Recall of Kian Pee Wan Capsules Due the Presence of Undeclared Dexamethasone and Cyproheptadine. FDA.gov, March 30, 2026.

Jared Clark is the principal consultant at Certify Consulting, with 8+ years of FDA regulatory experience across dietary supplements, food manufacturing, and medical devices. He holds credentials as a Registered FDA Regulatory Affairs Consultant (RAC), Certified Food Safety Quality Auditor (CFSQA), and Certified Professional Good Manufacturing Practices (CPGP), among others. Visit certify.consulting for compliance resources and consultation services.